Zoetis Inc.


SKU: ZTS Category:


Zoetis Inc.’s results were a major disappointment as it failed to meet Wall Street’s revenue and earnings expectations. The company’s performance for the third quarter attributes success to the diversified companion animal portfolio. The portfolio includes key dermatology products, pet parasiticides, monoclonal antibodies for osteoarthritis pain, and diagnostics. Despite ongoing challenges in the Chinese market, the company achieved an 8% operational growth in revenue and a 13% operational growth in adjusted net income. The balanced segment growth is evident, with 8% operational growth internationally and 8% growth in the US. The companion animal portfolio expanded by 11%, while the livestock portfolio saw a 3% operational growth in 3Q, aligning with overall expectations. As a market leader in animal health, their team anticipates strong growth driven by a steady pipeline of new products, life cycle innovation, and effective commercial execution. Their team is also confident in sustaining its key market-leading franchises, particularly in dermatology, pet parasiticide, and osteoarthritis pain. The company expects double-digit operational growth in the companion animal portfolio and low single-digit operational growth in the livestock portfolio. Emphasizing the human-animal bond, their team remains committed to investments, including direct-to-consumer programs and capabilities, to support growth while maintaining cost efficiency and creating shareholder value. Despite uncertainties, the management anticipates outpacing the market in 2023 and into 2024, driven by a diverse portfolio, industry-leading franchises, the launch of Librela, and operational excellence.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!